Clinical Trials Browser

Phase 1/2 × OTHER × Docetaxel × Clear all

NCT04577014 2026-02-11

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Phase 1/2 Recruiting

Sarcoma

NCT03598595 2026-02-04

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

Phase 1/2 Active not recruiting

Osteosarcoma

NCT05616624 2026-02-04

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT05256745 2025-12-24

RAGE

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Phase 1/2 Completed

Advanced Lung Cancer

NCT06615752 2025-11-12

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT05381038 2025-09-23

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Phase 1/2 Recruiting

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms, Neoplasms

NCT06531434 2025-09-22

Establishing Best Treatment Strategy for T4 Esophageal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Esophageal Cancer TNM Staging Primary Tumor (T) T4

NCT06704191 2025-09-22

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06732856 2025-07-28

NEO-CLAUD

Phase 1/2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02039336 2025-07-08

M13DAP

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT04947189 2025-05-15

4CAST

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms

NCT05319873 2025-05-13

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT06480110 2025-04-13

Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

Phase 1/2 Recruiting

Metastatic Castration-resistant Prostate Cancer

NCT03317158 2025-01-30

ADAPT-BLADDER

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02229084 2024-11-07

Vaccination of High Risk Breast Cancer Patients

Phase 1/2 Completed

58 enrolled 27 charts

Breast Neoplasms

NCT05816499 2024-06-17

AK104IIT018

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03095612 2024-06-13

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Terminated

41 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Phase 1/2 Completed

73 enrolled 18 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT02718820 2024-01-09

Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer

Phase 1/2 Completed

22 enrolled 10 charts

Head and Neck Carcinoma

NCT03837353 2023-12-18

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Phase 1/2 Terminated

18 enrolled 15 charts

Prostatic Neoplasms

NCT02834403 2023-12-15

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Phase 1/2 Completed

37 enrolled 20 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05777278 2023-10-10

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT02324543 2023-07-21

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Phase 1/2 Completed

47 enrolled 22 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT00129896 2023-03-06

Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients

Phase 1/2 Completed

Breast Neoplasms

NCT01879085 2022-09-21

GemTax

Phase 1/2 Completed

37 enrolled 17 charts

Neoplasm Metastasis, Sarcoma

NCT02494921 2022-08-31

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

Phase 1/2 Completed

43 enrolled 22 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT02447406 2022-06-15

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

Phase 1/2 Completed

Gastrointestinal

Advanced Gastric Adenocarcinoma

NCT04836156 2022-04-06

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

Phase 1/2 Recruiting

HER2-negative Early Breast Cancer

NCT00193128 2021-11-24

Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer

Phase 1/2 Completed

59 enrolled 8 charts

Gastrointestinal

Esophageal Neoplasms

NCT02565901 2021-10-01

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

28 enrolled 8 charts

Prostatic Neoplasms

NCT01217060 2021-04-13

Trimodality Management of T1b Esophageal Cancers

Phase 1/2 Completed

4 enrolled 8 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

NCT01468532 2021-03-25

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 1/2 Completed

18 enrolled 15 charts

Prostatic Neoplasms

NCT00456989 2019-10-30

Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer

Phase 1/2 Completed

39 enrolled 4 charts

Prostatic Neoplasms

NCT00669162 2019-07-24

Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

Phase 1/2 Completed

27 enrolled 7 charts

Prostatic Neoplasms

NCT03726736 2019-06-07

ACWDVDFPTAN

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00711243 2019-02-26

Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

Phase 1/2 Completed

59 enrolled 16 charts

Gastrointestinal

Stomach Neoplasms

NCT00318890 2019-02-05

Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck

Phase 1/2 Completed

Head and Neck Neoplasms

NCT00390429 2018-12-06

Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Phase 1/2 Completed

81 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03343977 2018-07-17

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Phase 1/2 Withdrawn

Metastatic Hormone-Sensitive Prostate Cancer

NCT02331251 2018-07-02

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Phase 1/2 Terminated

BreastGastrointestinalSarcomaThoracic

Breast Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT02379585 2018-04-24

STEFNE

Phase 1/2 Terminated

8 enrolled 1 chart

HER2-positive Breast Cancer

NCT02345772 2018-02-20

Neohttp

Phase 1/2 Terminated

4 enrolled 1 chart

HER2-positive Breast Cancer

NCT01418001 2018-01-11

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Phase 1/2 Terminated

5 enrolled 6 charts

Leiomyosarcoma, Sarcoma, Neurofibrosarcoma, Histiocytoma, Histiocytoma, Malignant Fibrous

NCT01921673 2017-07-14

Dovitinib Plus Docetaxel in Gastric Cancer

Phase 1/2 Completed

Gastrointestinal

Stomach Neoplasms

NCT00225420 2017-06-01

NRR

Phase 1/2 Completed

23 enrolled 9 charts

Prostatic Neoplasms

NCT00086957 2017-02-27

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Completed

31 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00879619 2017-02-01

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Phase 1/2 Terminated

4 enrolled 3 charts

Prostatic Neoplasms

NCT00452920 2016-12-15

Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer

Phase 1/2 Withdrawn

Uterine Cervical Neoplasms